<DOC>
	<DOCNO>NCT02116010</DOCNO>
	<brief_summary>The objective PHAGOBURN ass tolerance efficacy local bacteriophage treatment E. coli P. aeruginosa wound infection burn patient .</brief_summary>
	<brief_title>Evaluation Phage Therapy Treatment Escherichia Coli Pseudomonas Aeruginosa Wound Infections Burned Patients</brief_title>
	<detailed_description>PHAGOBURN Phase I/II clinical trial randomize , multicentric , open label , standard care ( Silver Sulfadiazine ) control aim assess tolerance efficacy local bacteriophage treatment wound infection due E. coli P. aeruginosa burn patient use Pherecydes Pharma anti-Escherichia coli anti-Pseudomonas aeruginosa bacteriophage cocktail GMP produce . This project European Research &amp; Development ( R &amp; D ) project fund European Commission 7th Framework Programme Research Development . This project involve 7 clinical site EU .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Sulfadiazine</mesh_term>
	<mesh_term>Silver Sulfadiazine</mesh_term>
	<criteria>Man woman Adult Informed consent obtain patient next kin Inhospital patient treat burn wound burn unit Burn wound ( graft ) graft harvest area , present local sign infection define SFETB criterion : A local locoregional inflammatory reaction ; And/or adverse unexpected local evolution ; And/or regard burn wound : presence pu , fast spontaneous debridement separation , occurrence blackish spot ( necrosis haemorrhage ) , unexplained conversion superficial lesion deep one ( &gt; 48th hour ) ; And/or regard graft donor site : presence pu , unexplained delay epidermisation , bedsore ; And/or regard graft recipient site : presence pu , lysis graft , necrosis fat locate graft . Burn wound microbiologically document infection , define positive surface swab , due Escherichia coli Pseudomonas aeruginosa whatever resistance profile Treated povidoneiodine Pregnant breastfeed woman Intercurrent condition require treatment may interfere analysis result : high dose chronic corticotherapy , immunosuppressive medication , oncologic chemotherapy Patient include interventional research protocol therapeutic intervention still ongoing upon inclusion time participate antiinfective drug trial previous month . Patient consider part vulnerable population Patient treatment limitation withdrawal study period consider Allergy Silver Sulfadiazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Wound Infection burn patient</keyword>
</DOC>